Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC

Oncologist - United States
doi 10.1634/theoncologist.2008-0108
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Role of KRAS-LCS6 Polymorphism in Advanced NSCLC Patients Treated With Erlotinib or Docetaxel in Second Line Treatment (TAILOR)

Scientific Reports
Multidisciplinary
2015English

The Effect of Combined Treatment With Sodium Phenylbutyrate and Cisplatin, Erlotinib, or Gefitinib on Resistant NSCLC Cells

Clinical Pharmacology: Advances and Applications
Pharmacology
2018English

MALDI Mass Spectrometry Imaging of Erlotinib Administered in Combination With Bevacizumab in Xenograft Mice Bearing B901L, EGFR-mutated NSCLC Cells

Scientific Reports
Multidisciplinary
2017English

P3.01-20 Advanced NSCLC Treatment and Outcomes After Nivolumab

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA15.02 Long-Term Safety and Clinical Activity Results From a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Radio-Immunotherapy: A Promising Weapon to Consider in the Fight Against NSCLC

International Journal of Radiology & Radiation Therapy
2017English

Shikonin Sensitizes Wild‑type EGFR NSCLC Cells to Erlotinib and Gefitinib Therapy

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

A Promising New Treatment Horizon for Haemophilia A

The Lancet Haematology
Hematology
2017English

RNA Interference: A Promising Approach for the Treatment of HBV Infection

Journal of Anesthesia & Intensive Care Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy